Topiramate 25 Mg 30 Tablets

Topiramate 25 Mg 30 Tablets

Description:

Topiramate 25 mg 30 tablets (topiramate 25mg 30 f.c.tab.) is a prescription oral anticonvulsant medicine used primarily for the treatment of epilepsy and for the prevention of migraine headaches. Each film‑coated tablet contains 25 mg of topiramate, a sulfamate‑substituted monosaccharide that acts as a broad‑spectrum antiepileptic and antimigraine agent. Topiramate helps stabilize neuronal membranes, reduce abnormal electrical activity in the brain, and decrease the frequency of seizures and migraine attacks. This product is intended for use under the supervision of a healthcare professional.

Indications:

• Monotherapy or adjunctive therapy in the treatment of partial onset seizures in adults and children (age limits depend on physician guidance).
• Monotherapy or adjunctive therapy for primary generalized tonic‑clonic seizures.
• Adjunctive therapy in seizures associated with Lennox–Gastaut syndrome (as directed by a neurologist).
• Prophylaxis of migraine headaches in adults and adolescents, to reduce the frequency and severity of migraine attacks (not for acute migraine treatment).
• Helps manage symptoms related to epileptic seizures such as loss of consciousness, involuntary movements, and sensory disturbances.

Active Ingredients / Key Components:

• Topiramate – 25 mg per film‑coated tablet.
• Inactive ingredients/excipients: Detailed excipient list and their concentrations , please check the product leaflet or the manufacturer’s official website. Refer to the official package leaflet for full composition.

Dosage & Administration / How to Use:

• Topiramate 25 mg tablets must be used exactly as prescribed by your doctor. Do not change your dose or stop treatment without medical advice.
• Tablets are taken by mouth, swallowed whole with water. Do not crush or chew unless your doctor specifically advises otherwise.
• Can be taken with or without food; taking with food may help reduce gastrointestinal discomfort in some patients.
• Epilepsy (general guidance – exact dose individualized): Treatment is usually started at a low dose (often 25 mg once daily at night) and gradually increased at weekly or longer intervals, according to response and tolerability. Total daily dose is commonly divided into 2 doses per day (morning and evening). Your neurologist will determine the appropriate maintenance dose.
• Migraine prophylaxis (general guidance – exact dose individualized): Therapy is usually initiated at 25 mg once daily and titrated gradually. The maintenance dose is determined by the physician based on clinical response and side effects.
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose. Do not double the dose to make up for a missed dose.
• Drink adequate fluids during treatment, as advised by your doctor, to reduce the risk of kidney stones.
• Use in children, elderly patients, and those with kidney or liver impairment requires careful dose adjustment by a physician.

Clinical Benefits:

• Helps control and reduce the frequency of partial onset and generalized tonic‑clonic seizures.
• Provides adjunctive benefit in difficult‑to‑treat epileptic syndromes such as Lennox–Gastaut syndrome, improving seizure control when combined with other antiepileptic drugs.
• Reduces the frequency of migraine attacks and may decrease the need for acute pain medications.
• Stabilizes neuronal membranes by modulating voltage‑sensitive sodium channels and inhibiting high‑frequency neuronal discharges.
• Enhances inhibitory GABAergic neurotransmission and inhibits excitatory glutamate receptors, contributing to its anticonvulsant and antimigraine effects.
• Exhibits weak carbonic anhydrase inhibitory activity, which may contribute to its overall pharmacological profile.

Warnings & Contraindications:

• Use only under medical supervision. This is a prescription medicine and should not be used without a doctor’s prescription.
• Contraindicated in patients with known hypersensitivity to topiramate or any component of the formulation.
• Topiramate may cause metabolic acidosis, kidney stones, and decreased sweating with increased body temperature, especially in children. Adequate hydration is important.
• May cause visual disturbances including acute myopia and secondary angle‑closure glaucoma. Seek immediate medical attention if you experience sudden vision changes or eye pain.
• Can cause mood changes, depression, and in rare cases suicidal thoughts or behavior. Inform your doctor immediately if you notice mood worsening, unusual behavior, or suicidal ideation.
• May impair cognitive function (difficulty with concentration, memory, or speech) and coordination. Use caution when driving, operating machinery, or performing tasks requiring alertness.
• Topiramate can decrease serum bicarbonate and may worsen conditions associated with metabolic acidosis. Caution in patients with renal disease, respiratory disorders, diarrhea, or those on ketogenic diet.
• Use with caution in patients with kidney or liver impairment; dose adjustment and close monitoring may be required.
• Topiramate may reduce the effectiveness of some hormonal contraceptives at higher doses. Discuss reliable contraception methods with your doctor.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Topiramate may cause harm to the fetus (including risk of birth defects); do not start or stop treatment in pregnancy without medical advice.
• Inform your doctor about all other medicines you are taking, especially other antiepileptic drugs, CNS depressants, carbonic anhydrase inhibitors, or medications affecting kidney function.
• Do not abruptly discontinue topiramate, as this may increase the risk of seizures. Any dose reduction or discontinuation must be gradual and supervised by a physician.
• Keep out of reach of children.

Side Effects:

• Common side effects: Tingling or numbness in hands/feet (paresthesia), loss of appetite, weight loss, dizziness, drowsiness, fatigue, difficulty with concentration or memory, slowed thinking, speech or language problems, nausea, abdominal pain, taste changes.
• Other possible side effects: Mood changes (irritability, depression, anxiety), insomnia, visual disturbances, double vision, coordination problems, tremor, kidney stones, decreased sweating, increased body temperature (especially in children), metabolic acidosis.
• Serious side effects (seek immediate medical attention): Sudden vision loss or eye pain, severe rash or allergic reaction (swelling of face, lips, tongue, or throat, difficulty breathing), severe abdominal or flank pain (possible kidney stones), signs of severe metabolic acidosis (rapid breathing, irregular heartbeat, extreme fatigue), suicidal thoughts or behavior, severe confusion or difficulty speaking.
• If you experience any unusual or persistent side effects, contact your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed in its original packaging to protect from moisture. Keep out of reach of children. Do not use after the expiry date stated on the pack. Do not store above the temperature specified on the package insert (temperature range not provided here; refer to the official leaflet).

Specifications:

• Product type: Prescription antiepileptic and antimigraine medicine.
• Strength: 25 mg topiramate per film‑coated tablet.
• Form: Film‑coated tablets for oral use.
• Pack size: 30 tablets per pack.
• Serving size: As prescribed by the physician (commonly 1 or more tablets per dose depending on indication and patient factors).

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.